David Wyles1, Norbert Bräu2,3, Shyam Kottilil4, Eric S Daar5, Peter Ruane6, Kimberly Workowski7, Anne Luetkemeyer8, Oluwatoyin Adeyemi9, Arthur Y Kim10, Brian Doehle11, K C Huang11, Erik Mogalian11, Anu Osinusi11, John McNally11, Diana M Brainard11, John G McHutchison11, Susanna Naggie12, Mark Sulkowski13. 1. Division of Infectious Diseases, Denver Health and Hospital Authority, Colorado. 2. James J. Peters Veterans Affairs Medical Center, Bronx. 3. Icahn School of Medicine at Mount Sinai, New York City, New York. 4. Institute of Human Virology, University of Maryland, Baltimore. 5. Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center, Torrance. 6. Ruane Medical and Liver Health Institute, Los Angeles, California. 7. Emory University, Atlanta, Georgia. 8. University of California, San Francisco. 9. CORE Center, Cook County Health and Hospitals System and Rush University Medical Center, Chicago, Illinois. 10. Massachusetts General Hospital and Harvard Medical School, Boston. 11. Gilead Sciences, Foster City, California. 12. Duke University, Durham, North Carolina. 13. Johns Hopkins University School of Medicine, Baltimore, Maryland.
Abstract
BACKGROUND: A safe, simple, effective, and pan-genotypic regimen to treat hepatitis C virus (HCV) infection in patients coinfected with human immunodeficiency virus type 1 (HIV-1) remains a medical need. We assessed the efficacy and safety of the NS5B polymerase inhibitor sofosbuvir and the NS5A inhibitor velpatasvir for HCV in patients coinfected with HIV-1. METHODS: This phase 3, open-label, single-arm study at 17 sites in the United States enrolled patients with HCV of any genotype and HIV-1 coinfection, including those with compensated cirrhosis. All patients received sofosbuvir-velpatasvir once daily for 12 weeks. The primary endpoint was sustained virologic response 12 weeks after treatment (SVR12). Efficacy and safety were assessed in all patients receiving at least 1 dose of treatment. RESULTS: Of 106 patients, 91 (86%) were men, 48 (45%) were black, and 19 (18%) had cirrhosis. SVR12 was achieved by 101 of 106 (95% [95% confidence interval {CI}, 89%-99%]) patients: 74 of 78 (95% [95% CI, 87%-99%]) with genotype 1; all 11 (100% [95% CI, 72%-100%]) with genotype 2; 11 of 12 (92% [95% CI, 62%-100%]) with genotype 3; and all 5 (100% [95% CI, 48%-100%]) with genotype 4. All 19 patients with cirrhosis had SVR12. Two patients relapsed, 2 were lost to follow-up, and 1 withdrew consent. Two discontinued treatment due to adverse events and 2 had serious adverse events. The most common adverse events were fatigue (25%), headache (13%), upper respiratory tract infection (8%), and arthralgia (8%). CONCLUSIONS: Sofosbuvir-velpatasvir for 12 weeks was safe and provided high rates of SVR12 in patients coinfected with HCV and HIV-1. CLINICAL TRIALS REGISTRATION: NCT02480712.
BACKGROUND: A safe, simple, effective, and pan-genotypic regimen to treat hepatitis C virus (HCV) infection in patients coinfected with human immunodeficiency virus type 1 (HIV-1) remains a medical need. We assessed the efficacy and safety of the NS5B polymerase inhibitor sofosbuvir and the NS5A inhibitor velpatasvir for HCV in patients coinfected with HIV-1. METHODS: This phase 3, open-label, single-arm study at 17 sites in the United States enrolled patients with HCV of any genotype and HIV-1 coinfection, including those with compensated cirrhosis. All patients received sofosbuvir-velpatasvir once daily for 12 weeks. The primary endpoint was sustained virologic response 12 weeks after treatment (SVR12). Efficacy and safety were assessed in all patients receiving at least 1 dose of treatment. RESULTS: Of 106 patients, 91 (86%) were men, 48 (45%) were black, and 19 (18%) had cirrhosis. SVR12 was achieved by 101 of 106 (95% [95% confidence interval {CI}, 89%-99%]) patients: 74 of 78 (95% [95% CI, 87%-99%]) with genotype 1; all 11 (100% [95% CI, 72%-100%]) with genotype 2; 11 of 12 (92% [95% CI, 62%-100%]) with genotype 3; and all 5 (100% [95% CI, 48%-100%]) with genotype 4. All 19 patients with cirrhosis had SVR12. Two patients relapsed, 2 were lost to follow-up, and 1 withdrew consent. Two discontinued treatment due to adverse events and 2 had serious adverse events. The most common adverse events were fatigue (25%), headache (13%), upper respiratory tract infection (8%), and arthralgia (8%). CONCLUSIONS: Sofosbuvir-velpatasvir for 12 weeks was safe and provided high rates of SVR12 in patients coinfected with HCV and HIV-1. CLINICAL TRIALS REGISTRATION: NCT02480712.
Authors: Y Benhamou; M Bochet; V Di Martino; F Charlotte; F Azria; A Coutellier; M Vidaud; F Bricaire; P Opolon; C Katlama; T Poynard Journal: Hepatology Date: 1999-10 Impact factor: 17.425
Authors: David L Wyles; Peter J Ruane; Mark S Sulkowski; Douglas Dieterich; Anne Luetkemeyer; Timothy R Morgan; Kenneth E Sherman; Robin Dretler; Dawn Fishbein; Joseph C Gathe; Sarah Henn; Federico Hinestrosa; Charles Huynh; Cheryl McDonald; Anthony Mills; Edgar Turner Overton; Moti Ramgopal; Bruce Rashbaum; Graham Ray; Anthony Scarsella; Joseph Yozviak; Fiona McPhee; Zhaohui Liu; Eric Hughes; Philip D Yin; Stephanie Noviello; Peter Ackerman Journal: N Engl J Med Date: 2015-07-21 Impact factor: 91.245
Authors: Susanna Naggie; Curtis Cooper; Michael Saag; Kimberly Workowski; Peter Ruane; William J Towner; Kristen Marks; Anne Luetkemeyer; Rachel P Baden; Paul E Sax; Edward Gane; Jorge Santana-Bagur; Luisa M Stamm; Jenny C Yang; Polina German; Hadas Dvory-Sobol; Liyun Ni; Phillip S Pang; John G McHutchison; Catherine A M Stedman; Javier O Morales-Ramirez; Norbert Bräu; Dushyantha Jayaweera; Amy E Colson; Pablo Tebas; David K Wong; Douglas Dieterich; Mark Sulkowski Journal: N Engl J Med Date: 2015-07-21 Impact factor: 91.245
Authors: Luz Martín-Carbonero; Yves Benhamou; Massimo Puoti; Juan Berenguer; José Mallolas; Carmen Quereda; Ana Arizcorreta; Antonio Gonzalez; Jurgen Rockstroh; Victor Asensi; Pilar Miralles; Montse Laguno; Leonor Moreno; José Antonio Girón; Martin Vogel; Javier García-Samaniego; Marina Nuñez; Miriam Romero; Santiago Moreno; Juan José de la Cruz; Vincent Soriano Journal: Clin Infect Dis Date: 2003-12-08 Impact factor: 9.079
Authors: Graham R Foster; Nezam Afdhal; Stuart K Roberts; Norbert Bräu; Edward J Gane; Stephen Pianko; Eric Lawitz; Alex Thompson; Mitchell L Shiffman; Curtis Cooper; William J Towner; Brian Conway; Peter Ruane; Marc Bourlière; Tarik Asselah; Thomas Berg; Stefan Zeuzem; William Rosenberg; Kosh Agarwal; Catherine A M Stedman; Hongmei Mo; Hadas Dvory-Sobol; Lingling Han; Jing Wang; John McNally; Anu Osinusi; Diana M Brainard; John G McHutchison; Francesco Mazzotta; Tram T Tran; Stuart C Gordon; Keyur Patel; Nancy Reau; Alessandra Mangia; Mark Sulkowski Journal: N Engl J Med Date: 2015-11-17 Impact factor: 91.245
Authors: Jordan J Feld; Ira M Jacobson; Christophe Hézode; Tarik Asselah; Peter J Ruane; Norbert Gruener; Armand Abergel; Alessandra Mangia; Ching-Lung Lai; Henry L Y Chan; Francesco Mazzotta; Christophe Moreno; Eric Yoshida; Stephen D Shafran; William J Towner; Tram T Tran; John McNally; Anu Osinusi; Evguenia Svarovskaia; Yanni Zhu; Diana M Brainard; John G McHutchison; Kosh Agarwal; Stefan Zeuzem Journal: N Engl J Med Date: 2015-11-16 Impact factor: 91.245
Authors: Michael P Curry; Jacqueline G O'Leary; Natalie Bzowej; Andrew J Muir; Kevin M Korenblat; Jonathan M Fenkel; K Rajender Reddy; Eric Lawitz; Steven L Flamm; Thomas Schiano; Lewis Teperman; Robert Fontana; Eugene Schiff; Michael Fried; Brian Doehle; Di An; John McNally; Anu Osinusi; Diana M Brainard; John G McHutchison; Robert S Brown; Michael Charlton Journal: N Engl J Med Date: 2015-11-16 Impact factor: 91.245
Authors: Christoph Sarrazin; Hadas Dvory-Sobol; Evguenia S Svarovskaia; Brian P Doehle; Phillip S Pang; Shu-Min Chuang; Julie Ma; Xiao Ding; Nezam H Afdhal; Kris V Kowdley; Edward J Gane; Eric Lawitz; Diana M Brainard; John G McHutchison; Michael D Miller; Hongmei Mo Journal: Gastroenterology Date: 2016-06-11 Impact factor: 22.682
Authors: Laura E Starbird; Chakra Budhathoki; Hae-Ra Han; Mark S Sulkowski; Nancy R Reynolds; Jason E Farley Journal: J Viral Hepat Date: 2019-12-09 Impact factor: 3.728